GHK-Cu is not an approved drug — it is a cosmetic ingredient with published human skin studies, but there is no established human dose for injection and no approved systemic use anywhere. This ghk cu dosage guide reports two separate evidence tracks: topical concentrations used in published human studies (skin and hair) and injectable doses used in animal research only. Nothing here is a recommendation — it is a map of what the science actually tested, so you can tell research from rumor.
The Short Answer
- Topical (human data): published skin studies used 0.5–3% GHK-Cu applied 1–2 times daily, typically for 8–12 weeks. Hair studies used 0.1–2%.
- Injectable (animal data only): published protocols range from 1 mg/kg to 20 mg/kg in mice and rats, depending on the model. There are no human injection trials.
- The “1–2 mg/day” figures you see online are community lore with no human-trial basis — documented below, not validated.
- One famous study isn’t what it seems: the widely cited “71-woman” GHK-Cu trial was a conference abstract that was never published as a full paper — and a later randomized trial found no objective benefit. Details below.
What Is GHK-Cu?
GHK-Cu (INCI name: Copper Tripeptide-1) is a complex of the tripeptide Gly-His-Lys with a copper ion (Cu²⁺). It was discovered in 1973 by Loren Pickart, isolated from a human plasma albumin fraction while studying why liver cells from young donors synthesized protein more actively than those from older donors. Unlike most research peptides, GHK-Cu is naturally present in human plasma, saliva, and urine — and its plasma concentration falls with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL at age 60 (Pickart & Margolina 2018).
It has been used as a cosmetic ingredient since the mid-1980s. That cosmetic history is exactly why GHK-Cu has something BPC-157 and TB-500 lack: published human studies — but only for topical use.
GHK-Cu Dosage for Skin: What Human Studies Used
Concentrations from published human skin research (these are study protocols, not recommendations):
| Study | Concentration & use | Result |
|---|---|---|
| Abdulghani et al. 1998 | GHK-Cu cream vs vitamin C vs tretinoin, head-to-head | 70% of GHK-Cu volunteers showed increased collagen — outperforming both controls |
| Leyden et al. 2002 ⚠️ | Facial cream 12 weeks (71 women); eye cream 12 weeks (41 women); thigh skin 12 weeks | Skin density/thickness up, laxity/fine lines down; 70% collagen improvement vs 50% vitamin C vs 40% tretinoin. ⚠️ Conference abstract only — never published as a full paper; manufacturer-funded. |
| Miller et al. 2006 (RCT) | Topical GHK-Cu after CO₂ laser resurfacing, 13 completers | No significant difference on objective measures (computer analysis, blinded grading) — only subjective patient questionnaires favored it |
| 3 mM cream study | Twice daily, 67 women aged 50–65, 12 weeks | Fine-line depth −27% (p<0.001) |
| 0.2% + 5% TBFE cream | Twice daily, 32 Asian adults, 8 weeks | Wrinkle, firmness, and elasticity improvements |
Two honesty notes most guides skip. First, the Leyden 2002 “71-woman study” — the single most cited GHK-Cu trial on the internet — exists only as a conference abstract. It was never peer-reviewed as a full paper, and it was funded by the product’s manufacturer. Second, Miller et al. 2006 is a randomized controlled trial with a negative result on every objective measure. A guide that cites Leyden but omits Miller is selling, not informing.
The practical pattern across studies: 0.5–3% topical, once or twice daily, 8–12 weeks to see measured effects. Ex vivo human-skin data shows a depot effect — about 82 µg/cm² retained in skin after 48 hours from a 0.68% application — consistent with slow local release rather than rapid systemic absorption.
GHK-Cu Dosage for Hair Growth: What the Studies Show
- Pyo et al. 2007: in human hair-follicle organ culture, GHK-Cu at 1 µM produced hair-shaft elongation comparable to 5% minoxidil — in a dish, not on a head.
- Uno & Kurata 1993: in a bald macaque model, topical GHK-Cu enlarged follicles comparably to minoxidil (small sample; macaques are not humans).
- Deckner et al. 2006: 2% GHK-Cu vs placebo vs 5% minoxidil — better than placebo, not significantly better than minoxidil.
- Lee et al. 2016 (Annals of Dermatology): GHK combined with 5-aminolevulinic acid in male pattern baldness patients, 6 months — significant hair-count increases (combination product, not GHK-Cu alone).
- Liu 2023 (Bioactive Materials): mouse model with ionic-liquid microemulsion delivery — anagen entry in 6 days vs 8 (free GHK-Cu) vs 9 (minoxidil).
Clinical-trial concentrations for hair: 0.1–2%, most commonly 1–2% topical. The honest summary of ghk cu dosage for hair growth: encouraging in vitro and animal signals, one human study showing parity-with-minoxidil at best — and several vendor claims circulating online (“67% more terminal hair,” a “Yonsei 2024 RCT”) that could not be verified against any publication and should not be repeated.
Injectable GHK-Cu: Animal Research Protocols Only
There are no human injection trials of GHK-Cu — no Phase I, no Phase II. Every injectable figure below is an animal protocol, not a recommendation:
| Model | Protocol | Source |
|---|---|---|
| Mouse LPS acute lung injury | 1 or 10 mg/kg i.p. daily × 3 days (prophylactic) | Park et al. 2016 (Oncotarget) |
| Mouse LPS lung model | 20 mg/kg intravenous, single | 2016 study |
| Mouse bleomycin lung fibrosis | 0.2, 2, 20 µg/g/day i.p. every other day (dose-dependent collagen reduction) | Zhang/Ma 2020 |
| Aged mouse cognition (sleep deprivation) | 15 mg/kg/day × 5 days i.p. | Rosenfeld 2023 |
| Rat oral wound | 2 mg GHK-Cu injected locally into wound chamber (local, not systemic — not weight-scalable) | Wound model study |
Note the range spans two orders of magnitude (1–20 mg/kg) across models — there is no single “injectable GHK-Cu dose” in the literature. Pharmacokinetics are thin: free GHK degrades in minutes (endogenous plasma half-life estimated at 15–30 minutes), and no formal ADME study of the intact complex has ever been published; human PK has never been measured by any route. One vendor’s claim of a “24–48 hour half-life” after subcutaneous injection contradicts every peer-reviewed review and should be disregarded.
GHK-Cu Dosage Chart: Quick Reference
All ghk cu dosing protocols from the published literature, condensed. Topical entries are human-study concentrations; injectable entries are animal protocols — never recommendations.
| Use studied | What the literature used |
|---|---|
| Skin (human) | 0.5–3% topical, 1–2×/day, 8–12 weeks |
| Hair (human/animal) | 0.1–2% topical, most commonly 1–2% |
| Systemic (animal only) | 1–20 mg/kg i.p. or i.v. in mice/rats, model-dependent |
| Wound (animal, local) | 2 mg injected locally into wound chamber (rats) |
| Community topical lore | 0.5–1%, 1–2×/day — no trial basis |
| Community injectable lore | 1–2 mg/day — no human-trial basis |
When comparing ghk peptide dosage figures across sources, always check which track the number belongs to — topical human data and injectable animal data are different worlds, and community figures belong to neither.
What About the “1–2 mg/Day” Figures Online?
Community-reported protocols (forums, wellness clinics) typically describe 1–2 mg/day subcutaneous as the most common figure, sometimes starting at 0.5 mg, in 4–8 week cycles with breaks — and 0.5–1% topical applied once or twice daily for 12–24 weeks. To be explicit: these have no human-trial basis whatsoever. The injectable numbers are not scaled from the animal literature by any standard method, and no human safety trial supports them. Documented here as a community phenomenon — not validated.
Safety: What the Literature Reports
- Acute toxicity is low: LD50 above 500 mg/kg i.p. in mice (Pickart & Margolina 2015) — a low-toxicity classification in the tested model.
- Topical safety: the Cosmetic Ingredient Review panel assessed GHK-Cu as safe in cosmetics at evaluated concentrations; adverse reports are limited to mild contact irritation or transient redness, usually vehicle-related. Note the panel evaluated low concentrations (around 0.1% order) while commercial products commonly use 1–3%.
- The real long-term question: a 2026 review flags cumulative copper burden from repeated injection or large-area use as the main concern — copper is a known contact sensitizer, and the intact complex’s fate in the body has never been formally mapped.
- No human injection safety data exists. That absence is the single most important safety fact.
Regulatory Status: Cosmetic ≠ Approved Drug
- Cosmetic ingredient: sold under INCI name Copper Tripeptide-1 since the mid-1980s; in the EU regulated as a cosmetic under Regulation (EC) 1223/2009 — which is not a therapeutic approval.
- Not a drug anywhere: no FDA-approved GHK-Cu drug exists; some sources incorrectly write “FDA approved for anti-aging skin creams” — the FDA does not approve cosmetic ingredients, so that claim is false on its face.
- FDA 503A compounding: non-injectable GHK-Cu is under Category 1 evaluation; the injectable nomination was withdrawn — an important detail most guides omit.
- Bottom line: legal in skincare, research-use-only for anything else.
Also read: our BPC-157 Dosage Guide for the same evidence-first treatment of research dosing protocols.
Frequently Asked Questions
How much GHK-Cu should I take?
There is no established human dose — so the question “how much ghk cu should i take” has no evidence-based answer. Published human research used 0.5–3% topical concentrations for skin (8–12 weeks) and 0.1–2% for hair. Injectable use has no human data at all — only animal protocols (1–20 mg/kg in mice/rats). Anyone quoting a ghkcu dosage in milligrams per day for humans is citing community lore, not research.
What is the GHK-Cu dosage for hair growth?
Clinical and preclinical studies used 0.1–2% topical, most commonly 1–2%. Evidence ranges from in-vitro parity with minoxidil (Pyo 2007) to a human trial showing improvement over placebo but not over minoxidil (Deckner 2006).
Can you inject GHK-Cu?
In published research, injection has only been studied in animals (mice/rats, 1–20 mg/kg depending on model). There are no human injection trials and no established human injectable dose. The FDA compounding nomination for injectable GHK-Cu was withdrawn.
How long does GHK-Cu take to work on skin?
Published topical studies measured effects at 8–12 weeks of once- or twice-daily application. Ex vivo data suggests a skin depot effect with slow local release.
Is GHK-Cu FDA approved?
Not as a drug — no GHK-Cu drug is FDA-approved. It is used as a cosmetic ingredient, which the FDA does not pre-approve. Claims of “FDA approval for skin creams” are incorrect.
Researching GHK-Cu? Start with verified material. Browse our GHK-Cu collection — every batch ships with HPLC and mass spectrometry documentation plus third-party COA verification, so the copper-peptide complex in your vial matches its label.
Advanced research: GHK-Cu vs Matrixyl — how the copper tripeptide’s evidence base compares with the palmitoyl pentapeptides dominating cosmetic peptide research.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. GHK-Cu is not approved as a drug by any regulatory authority; topical concentrations cited are from published human skin studies, and all injectable doses are from published animal studies — none are recommendations. Peptides sold on this site are for laboratory research use only and are not intended for human or veterinary use. Consult a qualified healthcare professional for medical decisions.
Leave a Reply